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Abstract
Background: Gastric adenocarcinomas comprise one of the common types of cancers in
Asian countries including Japan. Comprehensive protein profiling of paired surgical
specimens of primary gastric adenocarcinomas and nontumor mucosae derived from
Japanese patients was carried out by means of two-dimensional gel electrophoresis (2D-EP)
and liquid chromatography-electrospray ionic tandem mass spectrometry (LC-ESI-MS) to
establish gastric cancer-specific proteins as putative clinical biomarkers and molecular
targets for chemotherapy.
Results: Relatively common alterations in protein expression were revealed in the tumor
tissues. Increases in manganese dismutase and nonhistone chromosomal protein HMG-1
(HMG-1) were observed, while decreases in carbonic anhydrases I and II, glutatione-S-
transferase and foveolin precursor (gastrokine-1) (FOV), an 18-kDa stomach-specific
protein with putative tumor suppressor activity, were detected. RT-PCR analysis also
revealed significant down-regulation of FOV mRNA expression in tumor tissues.
Conclusion:  A possible pathological role for down-regulation of FOV in gastric
carcinogenesis was demonstrated. Evaluation of the specific decreases in gene and protein
expression of FOV in patients may be utilized as clinical biomarkers for effective diagnosis
and assessment of gastric cancer.
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Background
Gastric adenocarcinomas comprise one of the common
types of cancers in Asian countries including Japan, being
second only to lung cancer as to the number of deaths it
causes. In spite of the recent development of diagnostic
techniques, most gastric cancer patients are diagnosed at
an advanced stage and have a very low five-year survival
rate (less than 10%) [1]. This is partially due to a lack of
specific and sensitive biomarkers for the diagnosis and
monitoring of disease progress at an early stage, although
some gastric tumor markers, including the carcinoembry-
onic antigen, have been used and are partly effective. As
gastric carcinogenesis is a multistep process, comprehen-
sive analysis is also required for individual cases, in which
different molecular events occur in each carcinogenic
process.
Recently, proteomic analysis was utilized to comprehen-
sively examine protein expression in bodily fluids, tissues
and cells [2-4]. This approach, as clinical proteomics, is
very useful for identifying disease-associated proteins that
show changes in expression and modification corre-
sponding to a disease condition [5,6]. These disease-
related proteins are expected to be biomarkers for diagno-
sis and putative targeted proteins for treatment [7-9]. On
the other hand, comprehensive analyses of transcrip-
tomes in tumor tissues from various cancer patients using
DNA microarrays and gene chips have been performed in
recent years [10]. However, a lack of correlation between
changes in mRNAs and carcinogenesis has been demon-
strated, and quantitative and qualitative changes of post-
translationally modified proteins as final gene products
are considered to be more informative than those of
mRNAs in tumor tissues for studying the molecular events
in carcinogenesis. Proteomic studies for the identification
of tumor-associated proteins in gastric cancer are increas-
ing, and proteome databases for gastric tissues [11] and
cell lines [12] have been constructed. Most of them con-
cern specific proteins or antigens that reflect the chemo-
and thermo-resistant properties of stomach cancer [13-
15], and that are associated with Helicobactor pylori
[16,17]. In the present study, we performed comprehen-
sive proteome analysis of tumor and nontumor tissues in
Japanese patients with gastric carcinomas, and identified
several proteins of which the expression levels are com-
monly altered in clinical cases. In particular, the expres-
sion of gastrokine-1 (GKN-1) was suggested to be under
both transcriptional and translational control.
Results
Protein separation and identification
Figure 1A shows an image overview of a typical master gel
for a gastric tumor tissue. Around 200 protein spots
stained with Coomassie brilliant blue (CBB) R-250 were
well separated in the gels. The numbered spots in Figure
1B and 1C were excised from a gel, treated with trypsin
and then subjected to liquid chromatography-electronic
spray ionization tandem mass spectrometer (LC-ESI-MS/
MS) analysis. Seventy-two of them representing 69 differ-
ent protein species were identified. Table 1 lists all of the
proteins identified through peptide matching with the
Mascot search algorithm. The accuracy in protein profiling
was evaluated as the score value (above 37).
These proteins can be classified into several categories
based on their functions, including cytoskeleton proteins,
stress-related and chaperoning proteins, acute-phase pro-
teins, glycolytic enzymes, enzymes involved in metabo-
lism and cell proliferation, tumor suppressor proteins and
stomach-specific proteins.
Common alterations of protein expression between tumor 
and nontumor tissues in gastric cancer patients
Diverse alterations in proteomes were detected between
tumor and nontumor tissues from the same patients. As
shown in Figure 2, the several common alterations were
observed among in five Japanese gastric cancer patients
(Cases A to E). Manganese superoxide dismutase
(MnSOD), nonhistone chromosomal protein HMG-1
(HMG-1), phosphoglycerate kinase 1 (PGK-1), carbonic
anhydrase I and II (CA I and II), foveolin precursor FOV
(gastrokine-1), aspartate aminotransferase 2 precursor
(AST), and glutathione S-transferase (GST) exhibited
common changes in expression between tumor and non-
tumor tissues, including among the identified proteins.
The protein expression of MnSOD and HMG-1 was dem-
onstrated to be up-regulated in tumor tissues compared to
in nontumor tissues. On the other hand, the CA I and II,
FOV, AST and GST proteins were revealed to be down-reg-
ulated in tumor tissues. The fold changes in the expression
of these proteins relative to that of GAPDH are summa-
rized in Table 2. The most remarkable decrease was shown
in the level of FOV in all cases. The degree of the decrease
in GST protein expression was almost the same as that in
FOV (Cases B, D, and E), although one was not observed
in the other two cases. On the other hand, the increase in
HMG-1 was marked in three cases (A, C, and D), although
such a difference in expression was not observed in the
other two cases. MnSOD exhibited a tendency to increase
in the tumor tissues of three patients (Cases A, C, and D),
but a relative decrease was also observed in Case B. As for
PGK-1, a significant relationship between fold changes in
protein expression and the pathological grading of tumors
was hardly observed.
RT-PCR analysis
By RT-PCR, changes in mRNA expression in tumor and
nontumor tissues derived from gastric cancer patients
were analyzed for proteins that exhibited alterations in
protein expression, including FOV, MnSOD and HMG-1.Molecular Cancer 2006, 5:75 http://www.biomedcentral.com/1476-4598/5/75
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(A) An overview of a master 2D gel image for tumor tissue derived from a patient with a gastric adenocarcinoma Figure 1
(A) An overview of a master 2D gel image for tumor tissue derived from a patient with a gastric adenocarcinoma. (B) and (C) 
The numbered protein spots were identified by LC-ESI-MS/MS and protein matching, as shown as enlarged figures.
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Table 1: Protein profile detected in tumor tissue derived from a Japanese patient with a gastric adenocarcinoma.
Spot No. Accession number Protein identification Mass S.C. (%) pI Score
1 24308169 axonemal heavy chain dynein type 3 473776 0 6.04 37
2 15010550 heat shock protein gp96 precursor 90309 7 4.73 62
3 72222 heat shock protein 90-β 83584 14 4.97 176
4 5729877 heat shock 70 kDa protein 8 isoform 1 71082 19 5.37 283
5 38044288 gelsolin isoform b 80876 5 5.58 63
6 4826960 glutaminyl-tRNA synthetase 88655 1 6.71 44
7 4501867 aconitase 2 86113 10 7.36 231
8 119717 ezrin 69470 7 5.94 75
9 4557871 transferrin 79280 9 6.81 97
10 16507237 heat shock 70 kDa protein 5 72402 15 5.07 165
11 24234686 heat shock protein 70 kDa protein 8 53598 16 5.62 160
12 4885431 heat shock 70 kDa protein 1B 70267 11 5.48 143
13 1082886 tumor necrosis factor type 1 receptor-associated protein TRAP-1 75694 13 8.43 288
14 31542947 chaperonin, mitochondrial matrix protein P1, P60 lymphocyte protein 61187 13 5.7 299
15 28592 serum albumin 71316 23 6.05 292
16 340219 vimentin 53738 18 5.03 79
17 4503729 similar to FK506-binding protein 4 49031 5 5.6 36
18 32709 IFP53 53559 21 5.93 277
19 4502643 chaperonin-containing TCP1, subunit6A (zeta 1) 58444 6 6.23 79
20 7106439 tubulin, β5 50095 14 4.78 125
21 37492 α-tubulin 50810 13 5.02 94
22 125604 pyruvate kinase, M2 isozyme 58447 5 7.95 234
23 4557014 catalase 59947 6 6.9 120
24 4503483 eukaryotic translation elongation factor 2 96246 4 6.41 56
25 179279 ATP synthase β subunit 56861 5 5.39 59
26 7657041 down-regulated in metastasis 320846 2 7.07 40
27 4504169 glutathione synthetase, GSH synthetase 52523 5 5.67 99
28 12017952 GE36 73327 2 5.2 37
29 34234 laminin-binding protein 31888 12 4.84 51
30 16359158 actin, beta 42078 14 5.29 171
31 6635125 KIAA0284 protein 161473 2 6.36 47
32 5803225 14-3-3 epsilon 29326 8 4.63 49
33 4504707 inositol polyphosphate-4-phosphatase, type II, 105 kD 105749 1 5.87 37
34 35038601 hypothetical protein DKFZp761A078 74864 2 7.27 47
35 12017952 GE36 73327 1 5.2 38
36 4505877 plectin 1 isoform 1 520111 1 5.57 44
37 38158018 centrosomal protein 1, centriole associated protein, centriolin 269874 1 5.44 39
38 30157438 CTD-binding SR-like protein rA9 180240 1 9.15 41Molecular Cancer 2006, 5:75 http://www.biomedcentral.com/1476-4598/5/75
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39 4503471 eukaryotic translation elongation factor 1 α1 50451 12 9.1 191
40 4757810 ATP synthase 59828 17 9.16 178
41 693933 2-phosphopyruvate-hydratase α-enolase 47421 22 7.01 240
42 123576 47 kDa heat shock protein precursor 46352 14 8.27 177
43 5032069 splicing factor 3b, subunit 4 44414 3 8.54 58
44 4503471 eukaryotic translation elongation factor 1 α15 0 4 5 1 4 9 . 1 4 7
45 5921789 citrate synthase, mitochondrial precursor 51959 12 8.13 114
46 4505763 phosphoglycerate kinase 1 44985 14 8.3 87
47 4504069 aspartate aminotransferase 2 precursor 47844 6 9.14 52
48 7669492 glyceraldehyde-3-phosphate dehydrogenase 36201 13 8.57 49
49 4757756 annexin A2 38808 9 7.57 87
50 6648067 malate dehydrogenase, mitochondrial precursor 35965 7 8.92 60
51 5031857 lactate dehydrogenase A 36950 6 8.44 43
52 238427 porin 31 HM 30737 29 8.63 124
53 5174447 guanine nucleotide-binding protein 35511 8 7.6 65
54 34740329 heterogeneous nuclear ribonucleoprotein A3 39799 7 9.1 43
55 4504983 galectin-3 26229 12 8.58 42
56 4504447 heterogeneous nuclear ribonucleoprotein A2/B1 isoform A2 36041 7 8.67 40
57 86901 ATP-dependent DNA helicase RAP30/74 chain RAP30 26350 3 9.46 41
58 230445 carbonic anhydrase I 28903 12 6.44 67
59 455739 carbonic anhydrase II 29285 8 6.87 82
60 26892090 beta-globin chain variant 16101 40 7.86 121
61 34709 manganese superoxide dismutase 24891 10 8.35 111
62 4507645 triosephosphate isomerase 1 26938 17 6.45 47
63 38488935 foveolin precursor 20546 16 5.65 95
64 478813 nonhistone chromosomal protein HMG-1 25139 13 5.41 60
65 2204207 glutathione S-transferase 23595 34 5.43 73
66 178755 proapolipoprotein 28944 8 5.45 103
67 37267 transketolase 68435 4 7.9 59
68 189998 M2-type pyruvate kinase 58447 10 7.95 157
69 825605 glutathione S-transferase 25650 10 8.51 65
Table 1: Protein profile detected in tumor tissue derived from a Japanese patient with a gastric adenocarcinoma. (Continued)Molecular Cancer 2006, 5:75 http://www.biomedcentral.com/1476-4598/5/75
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As shown in Figure 3, FOV mRNA was significantly
decreased in tumor tissues in four at all patients (Cases A,
B, C, and E), while it was not detected in either nontumor
or tumor tissues from the other patient (Case D). On the
other hand, MnSOD mRNA was markedly increased in
four patients (Cases B, C, D, and E), although little differ-
ence in the mRNA level between nontumor and tumor tis-
sues in Case A was detected. However, a relationship
between HMG-1 mRNA expression and the pathological
phenotypes of tumors was hardly observed.
Discussion
In this study we performed proteomic analysis of tumor
and nontumor tissues derived from Japanese gastric aden-
ocarcinoma patients. Sixty-nine different proteins in the
tumor tissue from a gastric cancer case were identified by
2D-EP and LC-ESI-MS/MS, which included stress pro-
teins, Hsp70, Hsp90 and chaperonine-containing TCP1
(CCT), for self-protection; glycolytic enzymes, triose
phosphate isomerase 1, α-enolase and PGK-1, for the
growing energy requirement; cytoskeletal proteins, ezrin,
gelsolin isoform b and vimentin; proteins involved in cell
differentiation and proliferation, galectin-3 and transfer-
rin; and proteins exhibiting putative tumor suppressor
activity, FOV. Many of these proteins have been reported
to be associated with the tumorigenesis of gastric adeno-
carcinomas involving multiple steps and factors [18,19].
We also demonstrated that the expression levels of several
proteins in tumor tissues were commonly altered in five
Japanese patients with gastric adenocarcinomas, com-
pared to those in nontumor tissues. A common increase
Detailed alteration patterns of proteins Figure 2
Detailed alteration patterns of proteins. (A) Nontumor and (B) tumor proteins including CAI (No.58), CAII (No.59), MnSOD 
(No.61), FOV (No.63), HMG-1 (No.64), and GST (No.65). (C) Nontumor and (D) tumor proteins including PGK-1 (No.46), 
AST (No.47), and GST (No.69). GAPDH, circled, was used as a reference protein.
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in protein expression in tumor tissues occurred for
MnSOD, HMG-1 and PGK-1, whereas a common decrease
in tumor tissues occurred for FOV, GST and AST.
Superoxide (O2
-), a free radical, is essential for the anti-
microbial action of granulocytes and monocytes. Super-
oxide dismutase (SOD) rapidly removes the excess
amount of superoxide produced in the stress and biologi-
cal reactions in vivo through catalysis of the conversion of
superoxide with H+ to H2O2 and O2. MnSOD, one of the
SODs, is located in mitochondria and contributes to the
protection of mitochondrial DNA from damage. It has
been reported that enhanced expression of MnSOD in
progressive gastric cancer should be related to the 5-year
survival rate after surgery [20] and sensitivity to chemo-
therapy [21]. In this study, protein expression of MnSOD
was up-regulated in 4 of 5 gastric cancer patients, suggest-
ing a self-protecting response. On the other hand, the up-
regulation of MnSOD in tumor tissues has been consid-
ered to interfere with effective chemotherapy based on
radical production, which may cause a decrease in sensi-
tivity to anti-cancer drugs and determine the severity of
the cancer.
HMG-1 regulates the transcription of various genes and
the structural stabilization of chromosomes as a DNA-
binding protein. HMG-1 has been reported to be associ-
ated with carcinogenesis and metastasis in colorectal and
breast cancer [22].
Transcriptional up-regulation of HMG-1 in gastric cancer
has also been demonstrated [23]. Expression of HMG-1 in
tumor tissues was suggested to be related to resistance to
cisplatin [24]. We demonstrated here an increase in this
protein in three cases.
GST is a drug-metabolizing enzyme that catalyzes the con-
jugation of reduced glutathione to drugs and metabolites,
and also contributes to the detoxification of carcinogens.
Therefore, a decrease in the activity may be a risk factor for
carcinogenesis. Infection by Helicobacter pylori has been
reported to cause a decrease in GST expression [25], sug-
gesting that a decrease in GST activity might be a cause of
gastric carcinogenesis. In this study, a decrease in GST pro-
tein expression was observed in three cases. A decrease in
GST protein expression may be utilized as a biomarker for
the diagnosis of gastric tumors.
AST is an aminotransferase that acts on amino acids and
α-keto acid, that is distributed widely in human organs.
AST is released into the blood stream due to enhanced
permeability and destruction of tissues. A elevated con-
centration of AST protein has been reported in the blood
of patients with hepatitis, malignant tumors including
hepatomas, and leuchemia. Gene expression of GST has
also been demonstrated to be up-regulated in colorectal
tumor tissues [26]. However, a decrease in AST protein
expression was commonly observed in all tumor tissues
derived from the present five patients with gastric adeno-
carcinomas. Further study should be performed to eluci-
date whether a decrease in the AST protein is specifically
observed in gastric tumor tissues or not.
Elevated expression of PGK-1, which is one of the
enzymes in the glycolytic pathway and which catalyzes
the dephosphorylation of 1,3-bisphosphoglycerate to
Table 2: Fold changes in protein expression between nontumor and tumor tissues derived from five patients with gastric 
adenocarcinomas.
Protein Case A Case B Case C Case D Case E
C A  I- 6 . 5- 1 . 6- 3 . 3- 4 . 3- 2 . 6
CA II -2.6 -1.3 -26 -4.3 -13
FOV -13 -13 -26 * -26
MnSOD +1.7 -2.6 +6.5 +1.4 +1.1
HMG-1 +13 * +3.7 +13 *
PGK1 +1.6 +1.1 -1.2 +2.6 -1.4
AST -13 -1.6 -6.5 -3.7 -2.6
GST * -26 * -13 -13
CA I, carbonic anhydrase I.
CA II, carbonic anhydrase II.
FOV, foveolin precursor.
MnSOD, manganese superoxide dismutase.
HMG-1, nonhistone chromosomal protein.
PGK1, phosphoglycerate kinase 1.
AST, aspartate aminotransferase 2 precursor.
GST, glutathione S-transferase.
*, not determined.Molecular Cancer 2006, 5:75 http://www.biomedcentral.com/1476-4598/5/75
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produce ATP, has been observed in many malignant
tumor tissues that are dependent on ATP as a major energy
source. Solid tumors are thought to need the overproduc-
tion of ATP to maintain the enhanced proliferation. The
up-regulation of glycolytic enzymes, including PGK-1 in
lung cancer [27] and M2-type pyruvate kinase in colorec-
tal cancer [28], has been reported and suggested to be use-
ful for cancer screening. However, in the present study, a
significant relation between PGK-1 protein expression
and the phenotypes of gastric adenocarcinomas was
hardly detected. Therefore, PGK-1 was considered to be
not suitable for the diagnosis of gastric cancer.
Carbonic anhydrases (CAs) are zinc-containing enzymes
that are distributed widely in various organs and that
comprise a large family including CA-I to CA-IX. They cat-
alyze the hydration of CO2 for intermediate metabolism,
and maintain the pH and ion equilibrium in the body. So
far a direct relationship has been demonstrated between
malignant transformation and protein expression for CAs
I through VII [29]. Two earlier studies revealed that the
expression of both CA-I and CA-II was significantly
reduced in colorectal tumors compared to in normal
colorectal epithelia or mucosae [30]. Another report pre-
sented results showing that reduced expression of CA-I
and CA-II was correlated with the biological aggressive-
ness of colorectal cancer and synchronous distant metas-
tasis [31]. As suggested previously [32], gastric and
colorectal carcinomas may share a similar mechanism of
cell proliferation and mucosal malignancy, and may
become a biomarker for these carcinomas, because com-
mon decreases in the protein expression of CA-I and CA-
II were also observed in this study.
FOV, which is identical to a stomach-specific 18-kDa
antrum mucosa protein! (AMP-18) [33,34], GKN1 [35],
and trefoil factor interactions(z) (TFIZ) [36], was demon-
strated to be dramatically down-regulated or absent in the
gastric adenocarcinoma patients in this study. The human
AMP-18 and human carcinoantigenic CA11 gene product,
which encodes an amino acid sequence that differs from
that of AMP-18 in only a single residue [37,38], function
as secreted growth factors partly responsible for maintain-
ing a normal functional gastric epithelium [33]. Both
AMP-18 and the CA11 gene product have been reported
to be intensively expressed in normal stomach tissue but
not in most gastric cancers [33,37,38]. Immunohisto-
chemical studies demonstrated that AMP-18 appears to be
present in mucosal epithelial cells of the normal human
gastric antrum and duodenum [33]. Recently, TFIZ was
demonstrated to act as a growth regulator of gastric epi-
thelial cells through the formation of a heterodimer with
trefoil factor 1 (TFF1) [36]. Our present data further con-
firmed the high expression of FOV in nontumor gastric
tissues and the significant suppression of the protein in
gastric adnocarcinomas, indicating that FOV play roles in
Comparison of mRNA expression of proteins possibly associated with carcinogenesis between nontumor and tumor tissues  derived from five patients with gastric adenocarcinomas (cases A to E) by RT-PCR Figure 3
Comparison of mRNA expression of proteins possibly associated with carcinogenesis between nontumor and tumor tissues 
derived from five patients with gastric adenocarcinomas (cases A to E) by RT-PCR. N and T indicate nontumor and tumor tis-
sues, respectively.
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the maintenance of normal differentiation of epithelial
cells and tumor suppression but not in tumor tissues. Fur-
thermore, we demonstrated that transcription of FOV
mRNA was also commonly down-regulated in gastric can-
cer patients, indicating that a marked decrease in FOV pro-
tein was caused by suppression of FOV gene expression.
Furthermore, in one patient the protein was not detected
in nontumor tissues, suggesting that the expression level
of FOV protein in individuals may determine the gastric
adenocarcinoma phenotype. Accordingly, the expression
level of FOV as a biomarker may be informative for the
assessment of gastric cancer.
Conclusion
Protein profiling of tumor and nontumor tissues derived
from Japanese patients with gastric adenocarcinomas was
performed using 2D-EP and LC-ESI-MS/MS. The identi-
fied proteins included molecular chaperones, energy-pro-
ducing enzymes, cytoskeletal proteins, and so on.
Common protein alterations were detected in the gastric
cancer patients. Protein expression of MnSOD and HMG-
1 was up-regulated while that of GST, AST and FOV was
down-regulated in gastric tumor tissues. A correlation
between the alteration of these proteins and their tran-
scriptional expression in gastric cancer was hardly
observed in this study, except for in the case of FOV. Both
the protein and gene expression of FOV, a stomach-spe-
cific secretory growth factor for normal gastric epithelial
cells, was markedly down-regulated in tumor tissues
derived from Japanese patients with gastric adenocarcino-
mas. Monitoring of the expression levels of this stomach-
specific protein in clinical samples may provide useful
information for the diagnosis of gastric cancer as a specific
biomarker and for better understanding of gastric carcino-
genesis.
Methods
Materials
DNase I, RNase A, 2-mercaptoethanol (2-ME), glass beads
(212–300  µm), Nonidet P-40, acrylamide, N,N,N',N'-
tetramethylenediamine (TEMED), sodium dodecylsulfate
(SDS), iodoacetamide and dithiothreitol (DTT) were pur-
chased from Sigma (St. Louis, MO). Agarose for isoelec-
tronic focusing (IEF), and Pharmalyte pI 3–10, 4–6.5 and
8–10.5 were from Amersham Bioscience (Piscataway, NJ).
Trypsin (sequencing grade) was from Roche (Manheim,
Germany). Phenylmethylsulfonyl fluoride (PMSF), thiou-
rea, sorbitol, sodium pyrophosphate, ammonium persul-
fate, D,L-aspartic acid, trichloroacetic acid, sulfosalicylic
acid dihydrate, acetic acid, acetonitrile, formic acid and
trifluoroacetic acid (TFA) were from Wako Pure Chemi-
cals (Osaka, Japan). Urea was from Katayama Chemicals
(Osaka, Japan). Pepstatin A and leupeptin were from the
Peptide Institute (Osaka, Japan). NH4HCO3 and N,N'-
methylenebisacrylamide were from Nacalai Tesque
(Kyoto, Japan). CBB R-250 was from ICN Biomedicals
Inc. (Aurora, OH). Molecular mass standards were from
APRO Science, Inc. (Tokushima, Japan). TRIZOL reagent
was from Life Technologies (Frederick, MD).
Oligo(dT)12–18 primer, deoxynucleotides (dNTPs), and
RNaseOUT were from Invitrogen (Carlsbad, CA). M-MLV
reverse transcriptase and Taq DNA polymerase were from
Promega (Madison, WI).
Tissues and sample preparation
Primary gastric adenocarcinomas and adjacent nontumor
mucosae were collected on gastrectomy and provided by
the Dept. of Surgery, Graduate School of Medicine, The
University of Tokushima, Tokushima, Japan. The research
was carried out in accordance with the Declaration of Hel-
sinki of the World Medical Association, and was approved
by the ethical committee of the University of Tokushima.
Informed consent was also given by all of the patients
who provided the clinical samples. Tissues were frozen in
a dry ice-methanol bath as soon as possible after dissec-
tion and stored in a deep freezer (-80°C) before use. For
mRNA analysis, tissues were first immersed in RNAlater
(Takara, Tokyo, Japan) before freezing. Detailed clinico-
pathological data including the tumor stage (according to
the AJCC system), site and differentiation, and histologi-
cal data on the tissue samples are listed in Table 3. None
of these cases were classified in the scirrhous type cate-
gory, and tumor tissue was clearly distinguishted from
non-tumor one in each case. For two-dimensional gel
electrophoresis (2D-EP), protein extraction from tissues
was carried out by the following procedure. Frozen blocks
(20–30 mg wet weight) were homogenized with a plastic
pestle (Toyobo, Tokyo, Japan) in the presence of glass
beads in 10 vol/wet weight of dialysis buffer comprising 5
M urea, 1 M thiourea, 10 mM NaPPi, 1.67 µL/mL 2-ME,
0.005% DNase I, 0.05 mg/ml RNase A, 20 µM leupeptin,
1 mM EDTA, 2 mM PMSF and 20 µM pepstatinA, and
then centrifuged at 50,000 rpm for 30 min at 4°C (Beck-
man -Coulter, Fullerton, CA). The resultant supernatant
was used as the tissue extract. Protein concentrations were
determined with a Bradford protein assay kit (Bio-Rad,
Hercules, CA) using bovine gamma-globulin as a stand-
ard.
Two-dimesional gel electrophoresis
2D-EP was carried out as described previously [39]. The
first-dimensional isoelectric focusing was performed in an
1% (w/v) agarose gel (ϕ 2.6 × 180 mm) with a pH 3–10
gradient at 700 V for 18 hr at 4°C, and the second-dimen-
sional SDS gel electrophoresis was performed with a 5–
15% (w/v) acrylamide gradient (Mr range, 6–200 kDa) in
a standard slab gel (20 × 13 cm) at 15 mA for 3 h, and then
at 70 mA for 2 h at room temperature. Gels were stained
with CBB R-250.Molecular Cancer 2006, 5:75 http://www.biomedcentral.com/1476-4598/5/75
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Protein samples (500 µg) extracted from the tumor center
and surrounding histologically normal mucosa were sub-
jected to 2D-EP and run in pairs side by side.
Some of the stained spots were excised from the 2D-gel,
in-gel digested with trypsin and then subjected to LC-ESI-
MS/MS analysis as described previously [40]. The peptide
mixture was separated with a reversed phase nanoLC sys-
tem (Famous, Swichos II, Ultimate, LC Packings, Sunny-
vale, CA). The eluted peptides were sprayed directly into
an ESI mass spectrometer (Esquire3000 Plus, Bruker-Dal-
tonics, Fremont, CA).
A large volume of MS/MS data was acquired with DataA-
nalysis 3.1 software (Bruker-Daltonics), converted to text
files listing the mass values of the parent ions, and inten-
sities and masses of fragment ions, and then processed
with the MASCOT algorithm (Matrix Science Ltd, London,
U.K.) to assign peptides in the NCBI non-redundant
sequence database using a taxonomic restriction,
'human'. The database search was performed with the
parameters described by Yoshimura et al. [40].
Image analysis and MS peptide sequencing
Image acquisition and analysis were performed with
Molecular Imager FXProPlus (Bio-Rad) and ImageMaster
software (Bio-Rad). Comparisons were made between gel
images of tumor and matched nontumor samples pair by
pair. Normalized volume differences were statistically cal-
culated for all five cases. The content of glyceraldehyde 3-
phosphodehydrogenase (GAPDH) protein was used as a
reference to evaluate the fold alteration of protein expres-
sion between tumor and matched nontumor tissues as the
levels of GAPDH mRNA and protein were not changed
between tissues derived from patients. Consistently and
significantly different spots were selected for analysis by
LC-ESI-MS/MS. Protein spots!were cut out from gels in
small pieces, and subjected to in-gel tryptic digestion over-
night [40]. Peptide mass spectra were recorded, and
parameters for spectra acquisition were used as stated pre-
viously [40]. Accuracy in database protein matching using
Mascot Search [41] was judged as a score over 37, which
was obtained in most of the analyses.
RNA isolation and RT-PCR analysis
Tumor and matched nontumor samples (approx. 50 mg
wet weight) were minced, and then homogenized manu-
ally in 1 ml of TRIZOL reagent (Invitrogen) on ice. RNA
was isolated without DNase I treatment according to the
manufacturer's protocol. Briefly, 0.2 ml of CHCl3 was
added to the homogenate, followed by centrifugation at
20,600 × g for 15 min. An equal volume of 2-propanol
was added to the resultant supernatant to precipitate RNA.
After centrifugation, the pellet was rinsed with 75% etha-
nol/diethylpyridylchloride (DEPC)-treated water, fol-
lowed by drying. The pellet was dissolved in an
appropriate volume of DEPC-treated water as the total
RNA fraction. For reverse transcription (RT), 2 µg of RNA
from each sample was transcribed at 37°C for 1 h in the
presence of 200U of Molony leukemia virus reverse tran-
scriptase (Promega), oligo(dT)12–18  primer, 0.5 mM
dNTPs and 50U of RNaseOUT. The PCRs for carbonic
anhydrase-I and II, glutatione-S-transferase, FOV, and
GAPDH were performed within a linear range of amplifi-
cation using the selected primer set and conditions, and
expected size of products, as summarized in Table 4. The
PCR products were analyzed by 1.5% agarose gel electro-
phoresis and stained with ethidium bromide.
Abbreviations
2D-EP, Two-dimensional gel electrophoresis; 2-ME, 2-
Mercaptoethanol; AMP-18, Antrum mucosa protein-18;
AST, Aspartate aminotransferase 2 precursor; CA I and II,
Carbonic anhydrase I and II; CAs, Carbonic anhydrases;
Table 4: Primer sets used for RT-PCR analysis.
Primers Primer sequences
MnSOD sense 5' - acgcggcctacgtgaacaacctgaa - 3'
antisense 5' - aaccccaacctgagccttggacacc - 3'
HMG-1 sense 5' - cgggaggagcataagaagaagcacc - 3'
antisense 5' - caatggacaggccaggatgttctcc - 3'
GAPDH sense 5' - gtcatccatgacaactttgg - 3'
antisense 5' - tgctgtagccaaattcgttg - 3'
MnSOD, manganese superoxide dismutase.
HMG-1, nonhistone chromosomal protein.
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Table 3: Clinical features of the patients with gastric adenocarcinomas.
Case Age Sex Locationa Gradeb Stage
A 63 Male UM G3 IIIA T2N2M0H0
B 68 Female L G2 II T2N2M0
C 76 Male ML G2 IV T4N3M0
D7 8 F e m a l e L G 2 I I I T 2 N 0 M 0 H 0
E 77 Male ML G2 II T2N1M0
aU: upper, M: middle, L: lower
bG2: moderately differentiated, G3: poorly differentiated.Molecular Cancer 2006, 5:75 http://www.biomedcentral.com/1476-4598/5/75
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CBB, Coomassie brilliant blue; CCT, Chaperonine-con-
taining TCP1; DEPC, Diethylpyridylchloride; dNTPs,
Deoxynucleotides; DTT, Dithiothreitol; FOV, Foveolin
precursor (gastrokine-1); GAPDH, Glyceraldehyde 3-
phosphodehydrogenase; GKN1, Gastrokine-1; GST, Glu-
tathione S-transferase; HMG-1, Nonhistone chromo-
somal protein HMG-1; IEF, Isoelectronic focusing; LC-
ESI-MS/MS, Liquid chromatography-electronic spray ion-
ization-tandem mass spectrometer; MnSOD, Manganese
superoxide dismutase; PGK-1, Phosphoglycerate kinase 1;
PMSF, Phenylmethylsulfonyl fluoride; RT, Reverse tran-
scription; SDS, Sodium dodecylsulfate, SOD, Superoxide
dismutase; TEMED, N,N,N',N'-Tetramethylenediamine;
TFA, Trifluoroacetic acid; TFF1, Trefoil factor 1; TFIZ, Tre-
foil factor interactions(z).
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